Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,598.08
-21.3525-1.32%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,618.99
Open:1,618.99
Low:1,555.04
Close:1,619.43
Volume:75.27M
Turnover:6.47B
Market Cap:1.66T
Float Cap:1.60T

Loading ...

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Pfizer Says Litfulo Safety Profile in NSV Consistent with Alopecia Areata

Reuters
·
Oct 03

Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says

MT Newswires Live
·
Oct 03

Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline

TIPRANKS
·
Oct 03

Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise

TIPRANKS
·
Oct 03

Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone

TIPRANKS
·
Oct 03

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Oct 03

Pfizer Says Phase 3 Trials Show Litfulo Improves Repigmentation in Nonsegmental Vitiligo Patients at Week 52

Reuters
·
Oct 02

Pfizer - to Submit Litfulo Phase 3 Data to FDA and Ema

THOMSON REUTERS
·
Oct 02

Pfizer - Litfulo Safety Profile in Nsv Consistent with Alopecia Areata; no New Safety Signals

THOMSON REUTERS
·
Oct 02

Pfizer’s Litfulo Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo~

THOMSON REUTERS
·
Oct 02

Moderately bullish activity in Novo Nordisk with shares up 0.39%

TIPRANKS
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Tilray (TLRY)

TIPRANKS
·
Oct 02

Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 02